BBIO · BridgeBio Pharma, Inc. · Webcasts, Transcripts & Audio
$74.29
+0.02 (+0.03%)
At close · Nov 6
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$14.47B
Shares
194.80M
Volume · Nov 6
3.16M
Avg daily vol (3M)
2.7M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BridgeBio Pharma, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for BridgeBio Pharma, Inc. (BBIO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
Confident tone
Three near-term product launches
Incalorate for ADH1
BBP418 for LGMD2I
Revenue
$353.17M
▲ 192.6% YoY Diluted EPS
$-0.42
Gross margin
94.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
BridgeBio Pharma, Inc. (BBIO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
Confident tone
Late-stage pipeline / NDA submissions and PDUFA
Ex-US commercialization vs. partnership strategy
Path to profitability and operating leverage
Revenue
$243.68M
▲ 120.4% YoY Diluted EPS
$-0.78
Gross margin
93.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
BridgeBio Pharma, Inc. (BBIO) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
BridgeBio Pharma, Inc. (BBIO) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
BridgeBio Pharma, Inc. (BBIO) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
BridgeBio Pharma, Inc. (BBIO) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
BridgeBio Pharma, Inc. (BBIO) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
Confident tone
Atruvio (acoramidis) commercial momentum
Encaleret in ADH1 and chronic hypoparathyroidism
Infigratinib for achondroplasia
Revenue
$194.51M
▲ 66.8% YoY Diluted EPS
$-0.84
Gross margin
94.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
BridgeBio Pharma, Inc. (BBIO) March 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-10
BridgeBio Pharma, Inc. (BBIO) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
BridgeBio Pharma, Inc. (BBIO) March 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
BridgeBio Pharma, Inc. (BBIO) March 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
Confident tone
Atruby / ATTR cardiomyopathy commercial launch
Pipeline and Phase 3 catalysts
Tafamidis IP risk
Revenue
$154.18M*
▲ 2521.2% YoY Gross margin
94.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
BridgeBio Pharma, Inc. (BBIO) January 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-12-03
BridgeBio Pharma, Inc. (BBIO) December 3, 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-11-18
BridgeBio Pharma, Inc. (BBIO) November 18, 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-29
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
Confident tone
Attruby commercial performance
Infigratinib in achondroplasia
Encaleret Phase III CALIBRATE in ADH1
Revenue
$120.70M
▲ 4318% YoY Diluted EPS
$-0.95
Gross margin
94.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
Confident tone
Attruby commercial launch
Late-stage pipeline readouts
Clinical differentiation and best-in-class data
Revenue
$110.56M
▲ 4999.9% YoY Diluted EPS
$-0.95
Gross margin
96.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
Confident tone
Late-stage pipeline readouts
Pipeline expansion indications
TTR competitive positioning vs Acoramidis
Revenue
$116.63M
▼ 44.8% YoY Diluted EPS
$-0.88
Gross margin
97.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
BridgeBio Pharma, Inc. (BBIO) Q4 2024 Earnings Call
Revenue
$5.88M*
▲ 237.1% YoY Gross margin
64.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-23
BridgeBio Pharma, Inc. (BBIO) Q3 2024 Earnings Call
Revenue
$2.73M
▼ 33.2% YoY Diluted EPS
$-0.86
Gross margin
78.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-29
BridgeBio Pharma, Inc. (BBIO) Q1 2024 Earnings Call
Revenue
$211.12M
▲ 11461.9% YoY Diluted EPS
$-0.20
Gross margin
99.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-12
BridgeBio Pharma, Inc. (BBIO) Q3 2023 Earnings Call
Revenue
$4.09M
▲ 1110.4% YoY Diluted EPS
$-1.08
Gross margin
85.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-28
BridgeBio Pharma, Inc. (BBIO) Q2 2023 Earnings Call
Revenue
$1.64M
▼ 97.8% YoY Diluted EPS
$-0.98
Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
BridgeBio Pharma, Inc. (BBIO) Q4 2022 Earnings Call
Revenue
$1.87M*
▼ 85.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q1
2022-05-18
BridgeBio Pharma, Inc. (BBIO) Q1 2022 Earnings Call
Revenue
$1.69M
▲ 266.7% YoY Diluted EPS
$-1.35
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
BridgeBio Pharma, Inc. (BBIO) Q4 2021 Earnings Call
Revenue
$12.89M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q2
2021-08-13
BridgeBio Pharma, Inc. (BBIO) Q2 2021 Earnings Call
Revenue
$54.02M
Diluted EPS
$-0.66
Gross margin
99.8%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-22
BridgeBio Pharma, Inc. (BBIO) Q4 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-11
BridgeBio Pharma, Inc. (BBIO) Q2 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–31 of 31 webcasts
Key facts
CIK
1743881
CUSIP
10806X102
13F (30d)
209 filings
184 filers
Visit website
Investor relations